SightfileU.S. market data from official filings
Companies › NGEN
NERVGEN PHARMA CORP (NGEN)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001751912 · EDGAR filings · Updated 2026-07-02
NERVGEN PHARMA CORP (NGEN) has reported institutional ownership of 2.1%, with 44 institutional managers holding positions valued at $6.39M per the latest 13F reporting period.
Institutional ownership
2.1%
Institutional managers
44
Reported 13F value
$6.39M
Latest updates
- 2026-07-02 — Foreign issuer report (6-K) filed
- 2026-07-02 — SUPPL filed
- 2026-06-01 — Foreign issuer report (6-K) filed
- 2026-05-26 — EFFECT filed
- 2026-05-26 — Foreign issuer report (6-K) filed
- 2026-05-26 — SUPPL filed
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, NERVGEN PHARMA CORP has 44 institutional holders and institutional ownership of 2.1%.
Related companies
HARVARD BIOSCIENCE INC (HBIO) · Atossa Therapeutics Inc (ATOS) · MEDICUS PHARMA LTD (MDCX) · HEARTBEAM INC (BEAT) · INMUNE BIO INC (INMB) · APOLLOMICS INC (APLM)
See full history, cross-references and alerts on SightfileSightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.